Abivax (ABVX) Reiterated at Market Outperform by Citizens Ahead of ABTECT-UC Results

March 24, 2026 4:09 AM

Citizens analyst Jason Butler reiterated a Market Outperform rating and $131.00 price target on Abivax (NASDAQ: ABVX).The analyst commented, "Top-line ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found